Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

This study is testing an engineered immune cell therapy (CAR-T cells) that targets a protein called Claudin 18.2 (CLDN18.2), found on many stomach, pancreatic, and ovarian cancer cells, in patients whose cancer has stopped responding to standard treatments. **You may be eligible if...** - You are 18–70 years old with advanced gastric cancer, esophageal-gastric junction cancer, pancreatic cancer, or metastatic ovarian cancer - Your cancer cells test positive for CLDN18.2 (confirmed by a biopsy test) - You have no remaining standard treatment options - You have at least one measurable tumor site and a life expectancy of at least 12 weeks **You may NOT be eligible if...** - Your cancer is CLDN18.2-negative - You have serious heart, liver, kidney, or lung problems - You have uncontrolled infections or HIV - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.